LBA2 Impact of RNA expression signatures and tumour infiltrating lymphocytes (TILs) for pathological complete response (pCR) and survival after 12 week de-escalated neoadjuvant pertuzumab + trastuzumab ± paclitaxel in the WSG-HER2+/HR- ADAPT trial

M. Graeser,O. Gluz, C. Biehl, D. Ulbrich-Gebauer, J. Palatty, M. Christgen,S. Kuemmel,E-M. Grischke,D. Augustin,M. Braun, J. Potenberg,R. Wuerstlein, C. Eulenburg,R. Kates,C. Kolberg-Liedtke, F. Feuerhake, H. Kreipe, U. Nitz, N. Harbeck

Annals of Oncology(2021)

引用 4|浏览6
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要